Treatment of Metastatic HER2-Positive Breast Cancer

Podcast

Dr Kaklamani and colleagues highlight key clinical trials such as DESTINY-Breast01, HER2CLIMB, NALA, and SOPHIA in the setting of advanced HER2-positive breast cancer and discuss the practical considerations of these data.

Related Videos
Jason Jincong Freeman, PhD
Heather A. Parsons, MD, MPH
In this final episode of OncChats: Reviewing Best Practices in the Surgical Management of Breast Cancer, Gladys Giron, MD, FACS, and Cristina Lopez-Peñalver, MD, shed light on clinical outcomes following surgery of the primary tumor in patients with stage IV breast cancer.
Paolo Tarantino, MD
Erica L. Mayer, MD, MPH
A panel of 6 experts on breast, lung, and gastrointestinal cancers
Joseph A. Sparano, MD, FACP
In this fourth episode of OncChats: Reviewing Best Practices in the Surgical Management of Breast Cancer, Gladys Giron, MD, FACS, and Cristina Lopez-Peñalver, MD, discuss how to appropriately manage patients with stage IV breast cancer and outline when surgical approaches may be appropriate for this population.
Hope Rugo, MD, an expert on breast cancer, presenting slides
Mylin A. Torres, MD
Related Content
Aditya Bardia, MD, MPH

Datopotamab Deruxtecan Prolongs PFS in HR+/HER2- Inoperable or Metastatic Breast Cancer

December 7th 2023
Article
Yara Abdou, MD

Abdou Spotlights Factors Influencing ADC Treatment Selection in Breast Cancer

December 7th 2023
Podcast
Hope S. Rugo, MD, FASCO, of University of California San Francisco Helen Diller Family Comprehensive Cancer Center

Maintenance Pembrolizumab/Olaparib Misses Survival End Points in Locally Advanced or Metastatic TNBC

December 6th 2023
Article
Glenn J. Hanna, MD; Shravan Kandula, MD

FDA Approval Insights: Toripalimab in Recurrent/Metastatic Nasopharyngeal Carcinoma

December 4th 2023
Podcast
Stephanie Graff, MD

Persistent ctDNA Correlates With Disease Recurrence in HR+/HER2– Early Breast Cancer

December 6th 2023
Article
Mafalda Oliveira, MD, PhD

Capivasertib Maintains QOL Benefit Vs Placebo in HR+/HER2– Advanced Breast Cancer

December 6th 2023
Article